Acer Therapeutics Inc (fka ACER)

[J-Belfort]

https://pennystocks.com/featured/2021/03/14/5-biotech-penny-stocks-on-robinhood-to-watch-march-2021/

[C504]

If I am correctly reading the prospectus that was posted at 5pm on 2/12, there are approx. 2.5 million shares yet to be sold.

[J-Belfort]

I have a feeling many others who sold are thinking the same thing. 1 million of the 14m (12m public) changed hands. So that's the entry price for those shares. Many others held have higher entries pre june 2019. If it can run AH like that one random Friday, it can do much during regular session on real news. I held as I watched it bleed down to 2.50 like I'm sure you did. Hindsight is always 20/20 but you probably feel more comfortable with your position now. Since I bought it, I was of the mindset of "letting it ride" as it was very risky and remains so. I don't have a crystal ball just a big brass pair, so I remain betting on black as was my initial inclination when I got in less than 2 months ago.

[soliloquy]

Maybe I shouldn’t have sold half my shares. I had checked my account at a stop light a little after 4:00 pm and seen this jumped about 40% so I quickly pulled over and sold half my shares thinking it was an over reaction to something. Now I’m hoping that it’s not the merger happening yet. Crazy! I may of lost thousands instead of gaining hundreds from the sale

[J-Belfort]

12.5% of outstanding trades hands today...

[nothing-but-patience]

Summary Risk Factors from 10K is concerning, seems Relief is the better play?

[TurdBlossom]

According to the ACER 3rd Quarter Report on Nov 2020: “Regarding our emetine program, several in vivo studies are currently being conducted to evaluate the drug's safety and its specific activity against SARS-CoV-2 in the Syrian Golden hamster and ferret models. Coupled with the drug's in vitro data and emetine's long history of use in humans for other indications, we should have a good understanding of this candidate's potential as a therapeutic against COVID-19 relatively soon”

“Upcoming Milestones:
Anticipate in vivo efficacy results from ongoing animal studies evaluating emetine's anti-viral activity against COVID-19 by the end of the fourth quarter 2020
Targeting IND submission and potential initiation of the planned Phase 2/3 trial evaluating emetine in high-risk COVID-19 outpatients in the first half of 2021, subject to ongoing discussions with the FDA and additional capital”

[TurdBlossom]

Hello ACER longs, I apologize if this has been asked and answered, but I came over with the RLFTF crew and I hope someone can clarify where ACER-2820 (emetine) currently stands. From what I am able to find, ACER-2820 is a broad spectrum antiviral candidate which has been through a preclinical study for the potential treatment of COVID19 patients via subcutaneous injection. Do we know the results of the preclinical trial and are there sufficient resources available to continue the study? I read about possible capital via BARDA but am unable to find additional information or current status. Thanks in advance!

[J-Belfort]

I see you have found it by virtue of you posting here, the thing is that others will find it too. Thanks for stopping by early on to see how people catch multi baggers though.

Best,
JB

[4570govt]

And another one bites the dust.

[J-Belfort]

Highly volatile on low volume and many cashed out ~4.50 since they got <4 entries

Remember, for every share sold at a price, someone bought at that same price. Many have >4 entries and will wait for more news before even considering selling. They wouldn't have bought if they didn't see it as going up

[bridgrace]

JB,
Can you explain how they could get positive results and the price drops? What am I missing? TIA

[J-Belfort]

Study results released for ACER-001

https://www.globenewswire.com/news-release/2021/02/11/2174139/0/en/Acer-Therapeutics-Announces-Topline-Results-from-its-Bioequivalence-Trial-of-ACER-001-Compared-to-BUPHENYL-Under-Fed-Conditions.html

[J-Belfort]

Volume increasing, interest/dot-connecting happening. Massive pop incoming

[J-Belfort]

There will be more news coming that will significantly spur interest into this ticker. It will cause significant movement. Long Hold IMO.

Best,
JB

[J-Belfort]

Id say both: There will be others who figure out whats going on here, its just a matter of time. The outstanding shares are low, so there are not that many for sale honestly. I am not letting go and bought more on the dip since I originally got in above $4 but have now averaged myself much lower. I think the limited amount of shares makes this a really interesting one, it will remain volatile due to that

Best,
JB

[TurdBlossom]

ACER is up 11% on 1/3 of its usual daily volume. Someone connecting the dots or are we seeing the low float at play?

[J-Belfort]

Soon others figure out what ACER is going to be used for.

Best,
JB

[powerwalker]

It appears Acer has issued somewhere between 2-4 million shares since the 10-K was released. See below. I don't trust Yahoo! Finance in all cases, so I'm showing both sets of info.

Float, excluding institutions, is claimed to be less than 5 million, perY!F. If deal with Relief comes about, i.e., merger, then, FOMO could happen.

This is from the last 10-Q for 9/30:

Common stock, $0.0001 par value; authorized 150,000,000 shares;

11,912,731 and 10,095,176 shares issued and outstanding at

September 30, 2020 and December 31, 2019, respectively

Whereas, Yahoo! Finance has this on its stats page for Acer:

Share Statistics:
Avg Vol (3 month) 3 775.64k
Avg Vol (10 day) 3 884.68k
Shares Outstanding 5 13.92M
Float 4.97M
% Held by Insiders 1 25.21%
% Held by Institutions 1 37.47%
Shares Short (Jan 15, 2021) 4 207.27k
Short Ratio (Jan 15, 2021) 4 0.14
Short % of Float (Jan 15, 2021) 4 2.27%
Short % of Shares Outstanding (Jan 15, 2021) 4 1.49%
Shares Short (prior month Dec 15, 2020) 4 416.06k

P.S. I appreciate your advice and thoughts, JB, on all the companies involves.

[edna]

I am also thinking of the FOMO crowd on this one, but yes, lots of IFs. Thank you as always for sharing your thoughts on the market.

[J-Belfort]

I personally wouldn't sell my RLFTF shares solely to buy ACER shares but I see ACER as a extremely good buy though. Its more speculative and carries more risk than RLFTF but has huge potential due to its limited float. If in fact it turns out to be RLF's vehicle to get listed on NASDAQ if RLF-100 approval and ACER merger etc, It would be the only way Robinhood folks could get at it. Sure there will be RLFTF FOMO too but those smaller traders wouldn't be able to get to RLFTF due to it being an OTC in addition to the foreign transaction fees most would not want to incur. I would think a parabolic FOMO run would occur on ACER if that happens. Now that's a lot of "if's", so that would be why I would personally would not from sell RLFTF just in order to buy ACER.

Just my 2 cents though, I am into ACER with a decent amount as I averaged down to get below $4.

Best,
JB

[edna]

If one already holds RLFTF, would it make sense to sell and buy ACER or to simply hold RLFTF? Thanks as always for your perspective.

[J-Belfort]

I am of firm belief ACER is going to be the vehicle for RLF to be listed on the NASDAQ. Due to a limited float (10m - 2m held by insiders, so 8m) it will rocket once others make this connection. It remains a bargain at the current price. RLF top line results are pending and their US partner NRX's SPAC merger with NYSE:BRPA indicated that it is in fact going through. The BRPA S4 filed yesterday included sections on ACER as well. All part of plan devised by people with many years experience in M&A's. Thinly veiled but enough to blind some, just read between the lines.

Best,
JB

[J-Belfort]

RLF data read out coming...

It's in there on page 173

"NeuroRx is currently conducting Phase 2b/3 clinical trials, with read out data expected by January 28, 2021. Additional trials are being conducted"

BRPA S-4 Filed 01/27/2021

https://sec.report/Document/0001193125-21-019278/#d56937ds4.htm

[tcm55]

Taking RLF-100 to Market on the Nasdaq is a prime goal, Before Data is released. IMHFO.
NRXP seems to have dropped the ball. They have brought nothing but fluff from JJ and His company leech supposed connections. He PO'ed the DSMB/FDA and created these delays by releasing interim data and not expediting the Trial completion. Have they(NRX) paid bills or set up logistics-sales-OWS-? NO, RLF shareholders/GEM have allowed the progress. RLF owns the JEWEL of any Deal, RLF-100...
GEM wants this /any deal to get this on Nasdaq. ASAP... They want/need the investors/institutions. IMHFO. BEFORE DATA RELEASE, IMHFO...
BTW the urine syrup drug seems to fit the initial purpose of Aviptadil as an ED drug. BRPA was an elderly home investor co. Maybe these can all work out to MOVE FASTESTER. GOOD Data without a future plan may result in a pop and Not the Huge SPLASH we/GEM want...GLTA...

[bridgrace]

JB,
Thanks so much. Your insights are always so welcome.

[J-Belfort]

When the trial data comes out, all will benefit.

I do not believe RLF's interest is in ACERs drug for the maple syrup urine condition, there is an underlying motive imo.

I do know shares of ACER are limited, many dropped BRPA to move to ACER and more will follow soon.

Regardless, we must wait patiently and find out. Just holding

Best,
JB

[bridgrace]

JB, help me out here. You said they will all hit. But if RLFTF decides to merge with ACER instead of BRPA, doesn't BRPA drop back to $10? Also, do you think ACER will get a cut of RLFTF's profits or does their deal just give RLFTF a percentage of ACER's profts but not vice-versa? If the latter, then ACER will not really profit from RLF-100 success. Thanks so much.

[tcm55]

I see some RLF'ers here already.
Time for RLF to shake off the leeches at NRXP and go it alone. ACER could be a good shell to re-merge with for their NASDAQ listing.
RLF-100 is a patented Drug contained in their patents for VIP/RLF-100 formulations and MOA.
1 for 10 RS @ RLF and then use some of the new shares from Dec to seal the deal for ACER holders. Much simpler. Some established connections here at ACER appear much better than BRPA/NRX scamspac...GLTA...

[dmsrz8]

I just grabbed a small amount here. Looks interesting considering it’s history and any potential platform for RLFTF going to the Nasdaq

[J-Belfort]

Welcome aboard TB, this will rally like the others. Upon RCT data, they all will hit. This is THE "vehicle" IMO, ducks in a row & stars aligning.

Best,
JB

[TurdBlossom]

Just pulled the trigger and now I’m in RLFTF, BRPA trio, and now ACER. One play but so many different angles and opportunities. Let’s see where this rabbit hole takes us

[J-Belfort]

About 8m public shares out there, limited supply!

Latest 10K:
https://www.sec.gov/Archives/edgar/data/1069308/000156459020011639/acer-10k_20191231.htm

As of March 1, 2020, 10,095,176 shares of the registrant’s common stock, were outstanding. 150,000,000 shares Authorized but not issued.

As of March 1, 2020, our executive officers and directors and their affiliates beneficially owned or controlled approximately 19% of the outstanding shares of our common stock.


Get 'em while you can!

Best,
JB

[Tiger Money]

I sent u a pm

[J-Belfort]

TODAY it awoke... hold tight

[J-Belfort]

Great post!

[J-Belfort]

This will run more than that, I have "friends" coming

[J-Belfort]

Get in while you can, big things coming

[eom7]

Thank you!

[RAlbert]

[eom7]

Do you have the link?

[ClayTrader]

* * $ACER Video Chart 01-15-2021 * *

Link to Video - click here to watch the technical chart video

[jonny_red]

Yes indeed it is. Best entry price out there right now.

[RAlbert]

One you tuber recommending today.

[CyrusDaVirus]

This bitch gonna run hard to 12.5 soon

[jonny_red]

$ACER is making the move today. Worth checking it out.

[eom7]

I’ll be looking to add.

[Serious_Business]

yes , https://www.siliconinvestor.com/subject.aspx?subjectid=60187

$ACER
"Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health"

Q4 2020 is here, could be announcing the Covid 19 treatment news any day now. Also the other projects that are due Q4 2020. It has to be this week I'd imagine.

https://assets.wallstreet-online.de/_media/8763/board/20201215181357-screenshot-2020-12-15-non-confidential-corporate-.png
https://www.acertx.com/wp-content/uploads/2020/11/acer-public-slides-11-10-2020.pdf


https://www.globenewswire.com/news-release/2020/05/11/2031423/0/en/Acer-Therapeutics-to-Develop-Emetine-as-Potential-COVID-19-Treatment-in-Collaboration-with-National-Center-for-Advancing-Translational-Sciences-One-of-the-National-Institutes-of-He.html
https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/
https://saudijournals.com/media/articles/SJLS_59_165-169_hOtpmQp.pdf
https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/acer-therapeutics-teams-up-with-nih-to-develop-potential-covid-19-therapy-58570113

They also have other projects they are working on, Fresh PR from yesterday******
https://finance.yahoo.com/news/acer-therapeutics-announces-publication-vascular-133000437.html


https://www.linkedin.com/company/acer-therapeutics-inc
https://www.acertx.com/


• Acer’s pipeline includes four programs:

• Emetine for the treatment of COVID-19************************

• ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various
inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD)
• EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed
type III collagen (COL3A1) mutation
• Osanetant for the treatment of induced Vasomotor Symptoms (iVMS)
• Product candidates are believed to present a comparatively de-risked profile, having one or more of:
• Favorable safety profile; clinical proof-of-concept data; mechanistic differentiation
• Potential expedited paths for development through specific FDA-established programs
• Multiple anticipated key milestones:
• Emetine animal efficacy study results: Q4 2020 *******************************
• EDSIVO™ request FDA meeting to discuss confirmatory evidence plan: Q4 2020 **********************************
• Emetine IND submission and Phase 2/3 trial initiation*$: H1 2021
• ACER-001 BE fed trial completion: Q1 2021
• ACER-001 pre-NDA meeting with FDA: mid-H1 2021
• ACER-001 (UCD) NDA submission**$: Q2 2021
• Osanetant IND submission: Q2 2021
• Osanetant Phase 1/2 trial initiation*$: H2 2021


Volume is hot , last time volume was hot was in August and it went up to 5$
https://finance.yahoo.com/quote/ACER/key-statistics/

[eom7]

Did we just wake up here?

[TFMG]

$ACER | #AcerTherapeutics on Breakout List




Alert set for break above $4.70
Nice up trending channel formed, with midpoint
as current resistance.
RSI and Volume bullish
Golden cross complete
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.